SCHEMBL2249271

SCHEMBL2249271

COCCN[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.40
KMT2A Q03164 2/20 0.40
ALOX15 P16050 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
CA2 P00918 5/20 0.40
CA1 P00915 4/20 0.40
GGT1 P19440 1/20 0.39
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
NOD1 Q9Y239 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DDAH1 O94760 1/20 0.37
GGH Q92820 1/20 0.37
TSHR P16473 1/20 0.35
RIMKLA Q8IXN7 1/20 0.34
NAALAD2 Q9Y3Q0 1/20 0.34
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8904869 1.00 FOLH1 (0.40) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL8878008 0.90 TSHR (0.44) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL8878021 0.90 TSHR (0.44) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL9114355 0.86 GGH (0.50) FOLH1GGHRIMKLANAALAD2
SCHEMBL20813494 0.83 SLC1A1 (0.41) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL149082 0.82 KMT2A (0.48) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL5023601 0.81 NOD1 (0.46) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL2242496 0.81 NOD1 (0.46) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL23355119 0.81 GGT1 (0.44) FOLH1KMT2AALOX15BLMPMP22
SCHEMBL23355118 0.81 GGT1 (0.44) FOLH1KMT2AALOX15BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO disclosed
US-5698046-A REDUCES SPOTTING AND FILMING ON TABLEWARE THE PROCTER & GAMBLE COMAPNY (US) 1997-12-16 US disclosed
WO-1995007340-A1 BAR COMPOSITION WITH N-ALKOXY OR N-ARYLOXY POLYHYDROXY FATTY ACID AMIDE SURFACTANT THE PROCTER & GAMBLE COMPANY (US) 1995-03-16 WO disclosed
WO-1995007256-A1 N-ALKOXY POLYHYDROXY FATTY ACID AMIDES AND SYNTHESIS THEREOF THE PROCTER & GAMBLE COMPANY (US) 1995-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 FOLH1 17/4885KMT2A 2364/4885ALOX15 2170/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 FOLH1 17/4885KMT2A 2364/4885ALOX15 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.